The market for narrow imaging AI — a single tool that does one thing on one modality, cleared and validated — is being absorbed. Three acquisitions closed this quarter, each following the same pattern: a small company with one strong product and a thin sales motion, bought by a platform vendor with an enterprise contract already in place.

For radiology departments, the near-term effect is procurement simplification and the long-term effect is less clear. Suite pricing means a department may end up paying for eleven tools to get the two it wanted, and the acquired tools' independent validation records become harder to trace once they are versioned as part of a platform release.

Several academic departments have responded by insisting on per-tool performance reporting in contracts, including the ability to disable individual models without renegotiating the suite. Vendors have generally agreed, though the reporting granularity varies widely.

The founders we spoke with were mostly relieved. Selling a single-indication tool into hospital procurement is, by broad agreement, one of the least pleasant businesses in health technology.